

**Curriculum Vitae**  
**Robin T. Zon, M.D., FACP, FASCO**  
**July 2022**

**PERSONAL DATA**

**Citizenship:** USA  
**Home Address:** 30217 Stratford Ct.  
Niles, MI 49120

**Business Address:** Michiana Hematology-Oncology, P.C.  
5340 Holy Cross Parkway  
Mishawaka, IN 46545  
Telephone: 574-237-1328

**EDUCATION**

**2010- 2011** Executive Certificate in Business Administration  
University of Notre Dame, Mendoza College of Business

**Fellowship:  
1995-1998** Indiana University, Oncology & Hematology Fellow  
Chief Fellow 1997-1998  
Program Director: Lawrence Einhorn, M.D.

**Residency:  
1992-1995** St. Vincent Hospital and Health Care Center  
Internal Medicine, completed 6/30/95

**1988-1992** Indiana University School of Medicine  
M.D. completion date: May 1992

**1978-1982** University of Detroit, Detroit, MI  
Chemistry, B.S.  
Magna Cum Laude

**EMPLOYMENT HISTORY**

**May 2022- present** MHO Physician Emeritus  
Quality Officer ( QOPI, QCCA, PracticeNet, CancerLinQ)  
Practice Locum for distant sites of practice  
Zon Medical Advising LLC- pending consulting work

**April 1,2020  
-May 1, 2022** Cancer Specialist (moved over from MHO)  
*Chair Quality Assurance/Compliance Officer*  
*Physician Liaison Council*  
*QOPI Physician Liaison*  
*CancerLinQ Liaison*

*PracticeNet Liaison*  
*Integrative Care Partners Board Member*  
*QCCA executive Committee Member/Quality Chair/ MHO representative*

- January 2019** President/CEO Michiana- Hematology Oncology PC  
(Historic MHO Board Dissolved - 3/31/2020)
- To *QCCA executive Committee Member and MHO representative*  
*Integrative Care Partners Board Member and Founding Member*
- March 31,2020** *CancerLinQ Liaison*  
*PracticeNet Liaison*  
*Quality Care Assurance/Compliance Liaison Officer*  
*Quality Oncology Practice Initiative Certified Physician/liaison*  
*Contract Review Committee*  
*Finance Committee Chair 2014- present*
- July 1998-  
December 2018** Michiana Hematology-Oncology, P.C.  
*Vice President/Partner, Medical Oncology*  
*Quality Care Assurance/Compliance Liaison Officer*  
*Quality Oncology Practice Initiative Certified Physician*  
*Contract Review Committee*  
*Finance Committee Chair 2014- present*  
*CancerLinQ liaison 2014-present*
- 1999-June 1, 2013** NCI CCOP Associate, and main Principal Investigator  
Medical Director for Oncology Research, Memorial Hospital of South Bend
- April 2013-2018** Medical Protective Advisory Board for Internal Medicine  
Serving as paid consultant
- 1999-2004** Medical Director of Oncology, Elkhart General Hospital
- 1987-8/88** BOEHRINGER MANNHEIM DIAGNOSTIC COMPANY  
*Research Investigator – Diagnostic Kit Development*  
Total responsibility for establishing laboratory dedicated to development of a new Home Test Cholesterol Kit based on technology transferred through intensive negotiations with Germany. Acted as support lab for AccuCheck Glucose Revised Strip. Responsible for coordination technical, developmental, manufacturing, business modeling and marketing aspects of projects. Skills included data analysis, technical knowledge, budgeting, supply chain analysis, marketing analysis, computer usage, public speaking and report writing. Served on team lead responsible for developing Research and Development Center in the United States.
- 1985-1987** MERRELL-DOW RESEARCH INSTITUTE  
*Research Biochemist – Pharmacology*  
Developed in vitro, in situ and in vivo models for evaluation of Phase I Trial Study hypocholesterolemic agents and recommended further compound synthesis. Developed assays for isolation/detection of experimental compounds by HPLC, GLC, UV/VIS. Analyzed all data via SAS computer program.

- 1982-1985** MERRELL-DOW RESEARCH INSTITUTE  
*Chemist – Pharmacology*  
 Developed and implemented assays to elucidate mechanism of action of Lorelco and other hypocholesterolemic agents for Phase I Trial studies including GLC/Fluorescent techniques to quantify cholesteryl Esters. Co-author of paper presented to the International Symposium on Cardiovascular Disease, Australia, 1985.
- 1981-1982** MERRILL-DOW PHARMACEUTICAL, INC.  
*Quality Control Co-op*  
 Analyzed materials for manufacturing via HPLC/GLC methods. Completed liquid Formulation products stability studies. Developed HPLC method for quantifying Lorelco formulations.
- 1980-1981** DOW CHEMICAL COMPANY  
*Technical Service and Development Co-op*  
 Provided technical support for oxides and intermediates labs. Designed and implemented use of glycol ether bottoms in cleaning products as alternative to waste disposal. Handled customer product inquiries.

### CERTIFICATIONS/LICENSES

State of Indiana, issue date July 1, 1993 - #01041630A  
 State of Michigan, issue date- 2009 -2014  
 American Board of Internal Medicine – Internal Medicine, 1995  
 American Board of Internal Medicine – Medical Oncology, 1998, recertified to 2028  
 Human Participants Protection Education for Research Teams sponsored by the NIH, 05/2018  
 Maintenance of Certification Program- enrolled and actively participating, met all requirements

### American Society of Clinical Oncology Committee /BOD Volunteer Activities (2000-2020)

Cancer Education Committee 2000-2003  
 Cancer Prevention Committee 2003-2010  
**Chair**, Reimbursement sub-committee 2007-2008  
**Chair**, Prevention in Practice sub-committee 2008-2010  
**Chair-elect**, Cancer Prevention Committee 2009  
 Survivorship Committee 2005  
 Cancer Research Committee 2006-2010  
**Chair**, Exemplary Attributes sub-committee 2007-2010  
 Clinical Practice Committee 2007-2010  
 Liaison to Prevention Committee  
 Clinical Practice Committee Steering Subcommittee 2007-2010  
 Clinical Trials Workshop Committee (USA) 2003-2008  
**Co-Chair** Clinical Trials Workshop Committee 2004-2005  
 International Clinical Trial Workshop 2009-2014  
 Speaker/Organizer Argentina Workshop 2009  
 Speaker/Organizer Cairo Workshop 2010  
**Chair**, CTPA Award committee 2006-2010  
**Chair**, CORG Grant committee 2007-2009  
 Journal of Oncology Practice reviewer and article contributor 2005-present

ASCO University Module Reviewer -Presenter  
Breast Cancer Guideline Advisory Group 2011-2014  
**Board of Directors 2010-2013**  
Board Liaison to Quality Care Committee  
Research, Policy and Practice Subcommittee  
Health plan Policy Review Advisory Group, Chair  
Board Liaison to Leadership Development Program  
President-elect Nominee 2012 election  
**Chair-elect**, Clinical Practice Committee, 2013-2014  
Payment Reform Workgroup  
Provider Payer Initiative Co-Chair  
Practice Policy and Emerging Issues Workgroup Co-Chair  
**Chair, Clinical Practice Committee**, 2014-2015, **Immediate Past-Chair** 2015-2016  
Payment Reform Workgroup  
Practice Policy and Emerging Issues Workgroup Co-Chair 2013-2015  
Provider-Payer Initiative Co-Chair 2014  
CAC Advisory Meeting Co-Chair 2014  
Practice Administrators Workgroup  
Pathways Task Force Chair, 2015- present  
President-elect Candidate 2015 election  
**Chair-elect** Government Relations Committee, 2016-2017  
**Chair Government Relations Committee** 2017-2018  
**Past-chair** Government Relations Committee 2018-2019  
CancerLinQ Data Governance committee 2014-2017  
MACRA Task Force 2016-2017  
**Pathways Task Force Chair** 2015- 2019  
**Editor -Elect** of State of oncology Care in America (SOCCA) 2019 -2020  
**Mentor** for ASCO Health Policy Leadership Development Program 2019-2020  
ASCO PAC – 2020-present  
ASCO Healthcare Delivery Task Force COVID 2020  
ASCO Chair of State of Oncology Care in America (SOCCA) **2020-2021**  
ASCO Co- chair for Telemedicine Guidelines 2020-2021  
**JCO-OP and JCO manuscript reviewer**  
**ASCO Liaison Representative to Board of Directors for NAPBC 2021-2024**

*CancerLinQ Board of Governors:* Community Representative 2019 – 2022

*Woman Who Conquer Cancer* 2018-2022

### **ASCO Related Presentations:**

#### ASCO Annual Meeting Presentations

2009 Presenter: Optimizing Your Practice with an Eye to Efficiency, Research and Quality

2010 Chair : Implementing Clinical Trials: Risks, Benefit, Marketing and Paying For It All

2010 Presenter : Structuring/Marketing a Program for Success

2014 Chair : The Changing Landscape of Federally Sponsored Trials

2014 Presenter : Community Involvement in Clinical Trials: From CCOP to NCORP

2015 Chair and Presenter Extended Education Session: Administrative Burdens in Oncology

2015 Presenter Women Networking : Private Practice Experience

2016 Chair and Presenter: Practicing in the Age of Value-Based Clinical Pathways

2016 Chair and Presenter: MACRA Townhall

2016 Presenter Women Networking – Negotiating Salaries

2017 Chair and Presenter : Guidelines and Pathways for the Practicing Oncologist

2018 Town Hall : Utilization Management , Fellows mentor

2019 Women in Oncology Mentor , Mentor for Fellows Discussant in Meet and Greet

2020 National Academy of Sciences- Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic Workshop

2021 National Academy of Sciences Workshop- Electronic Health records for Oncology Care, Research, and Surveillance

2022 NIH/NCI-Telehealth In Oncology

2022 Poster Discussant “Optimizing Telehealth for the Future Post Pandemic”

2022 Fellow Mentoring Town Hall- Contract Negotiations

2022 MASCC/ISO “Lessons Learnt from the ASCO Telehealth in Oncology Standards and Recommendations “

2022 ASCO Direct ( July ) Telemedicine

ASCO Oncology Practice Conference Leadership and Presenter

2017 and 2018 Chair of Meeting - Presenter and panelist in both meetings

2019 Past Chair of Meeting – session chair, presenter

ASCO State of Cancer Care Capitol Hill Presentations: 2015, 2017

ASCO Podcasts ( 2 ) 2021

**Research Activities**

*Summary: While PI of the NICRC CCOP I recorded a Personal Accrual activity between 1999-2013 of over 1,250 pts enrolled on clinical trials. I served as PI of over 100 protocols(CCOP PI and/or local PI). The total NICRC-CCOP accrual between 1999-2013 was over 5000 pts, resulting in over 100 publications and 20+ presentations at national meetings. NICRC-CCOP was a top ten performing CCOP. I was also the Community PI for E2100 published in NEJM. Also served in leadership capacity for the NCCTG, Alliance, NCTCN and NCORP. Mentored and trained all the NICRC research staff, including the administrator, as well as mentored all the sub-PIs who had never participated in clinical research.*

***Northern Indiana Cancer Research Consortium (NICRC)***

**Immediate Past Principal Investigator 2013- 2017**

**Principal Investigator (CCOP) 2005-2013**

**Principal Investigator of Cancer Control and Prevention (CCOP) 1999-2005**

Board of Trustees 1999-2017

Marketing Committee 1999- 2017

Finance Committee 1999-2017

Investigator 1999-2017

Founder, Editor of Cancer Research Today 2007-2014

***Alliance (formerly NCCTG)***

Alliance Board of Directors 2009- 2015  
Alliance Executive Committee 2014- 2015  
Alliance PI 2009-2015

***NCTN***

NCTN Steering Committee Work Group member 2012-2014

***NCI/NCORP***

**Chair** of the NCORP Evaluation Committee 2017

***Hoosier Oncology Group( now known as Hoosier Cancer Research Network)***

Executive Committee 2006-2010, 2002-2004, 1999-2001  
Education Chair 1999-2005  
**Vice Chair/Co-chair** 2006-2010

***Scientific Leadership Council in Breast Cancer***

Coalition of Cancer Cooperative Groups 2006

***Congress on Clinical Pathways : Steering Committee Member and Presenter 2016- 2022***

**Local and State Community Activities**

***South Bend Medical Foundation***

Board of Directors 2016- present

**Vice Chair** 2017-2021

**Chair** 2021-2022 and CEO Search Committee Chair

\*\*\* provided significant leadership in major sale of diagnostic division 2018-2020 \*\*\*

***Trinity Healthcare System Oncology Excellence Committee & Oncology Pathways Committee  
Cancer Society of St. Joseph County***

Board of Directors 1998-2010

***The Center for Hospice and Palliative Care***

Board of Directors 2004-2009

***Susan G. Komen Northern Indiana Affiliate***

Board of Directors 2006-2010

***Indiana Cancer Consortium (ICC) (CDC State Cancer Control Plan)***

Steering Committee 2001-2006

Breast Cancer Committee **Co-Chair** 2002-2004

Prevention Committee **Co-Chair** 2004-2006

**ICC Co-Chair** 2002 to 2006

***Hospital Committees***

Oncology Care Committee, Memorial Hospital of South Bend, 1998 to 2014

Technology Assessment Committee, Memorial Hospital of South Bend, 2001 to 2009

ACOS Cancer Liaison Physician, Elkhart General Hospital, 1999 to 2004

Blood Transfusion Committee, Elkhart General Hospital, 1998 to 1999

Oncology Care Committee, Elkhart General Hospital, 1998 to 2004

***Outreach Clinic***

Second Opinion Breast Cancer Clinic, Elkhart General Hospital, 2001 through 2004  
**Cancer Liaison Physician (ACOS)**, Elkhart General Hospital 1999-2004  
**Indiana Medical Oncology Society (IMOS)**  
 Board of Trustees 2002-2004  
**American Cancer Society**  
 Board member 2000  
**Indiana University Physicians Advisory Council** 2001  
**American College of Physicians (ACP)**  
 Annual Session, Speaker 1999  
 Publication and Policy Committee 1994-1995  
 Associate Representative to Residency Review Committee 1994-1995  
 Appointment to National Council of Associates 1993-1995  
**National Consortium of Resident Physicians Organizations**  
 Chair 1994-1995  
 Vice-Chair/Forum Planner 1993-1994  
**AAMC**  
 Official Student Representative (OSR) to NRMP board of Directors 1991-1993  
 OSR 1990-1992  
**AMWA**: Chapter President 1991

**Mentorship activities** : over the years I have mentored many oncology nurses and research staff, Fellows, Residents , Medical students, as well as members of the many ASCO committees I have served. The following highlights examples:

- Alicia Dumkowksi, trained her to be the Administrator of the NICRC CCOP
- Bobby Daly MD, Assistant Attending, Thoracic Oncology, Memorial Sloan Kettering
- Jennifer Ewing NP. Chief Operations Officer of MHO PC
- Wendy Allen-Rhoades MD, Senior Associate Consultant, Pediatric Hematology/Oncology, Mayo Clinic,
- Laura Tenner MD MPH, GI Medical Oncologist, Associate Professor, UT Cancer Center MD Anderson
- Joyce Simpson MD CEO and President of South Bend Medical Foundation
- Bobbie Sutton MD, Lab Director and VP of True Health Diagnostics, Director of Pathology, Sky Ridge

Bristol-Myers Scribbs –BeNow Presenter and Panel Moderator – March, June 2021

### **Fundraising Activities**

The Montessori Academy Elementary School- \$ 100,000  
 Conquer Cancer YIAs- jazz event at my home (2016) – \$ 224,000 supported 3 ½ YIAs  
 Logan Center for Autism – 2 events held at my home - \$750,000 combined  
 Conquer Cancer Foundation -YIA 2022

### **PROFESSIONAL AWARDS**

Danielson Award for Research – Hoosier Oncology Group, 2005  
 Hope Award – American Cancer Society, August 2008 ENACCT education grant - 2009  
 ENACCT education grant - 2009  
 Hoosier Oncology Group Clinical Trial Participation - 2010  
 National Cancer Institute Individual Physician High Accrual Award 2012

National Cancer Institute Platinum Certificate of Excellence for Clinical Trial Accrual as PI of NICRC–  
2011,2012

ASCO Clinical Trial Participation Award – 2008 & 2014

Fellow of the American Society of Clinical Oncology (FASCO)- June 2013

ASCO Advocate of the Year Award 2016

ASCO Advocacy Presidential Circle Award 2017-2022

**ASCO Distinguished Achievement Award 2020**

## **PUBLICATIONS/POSTER PRESENTATIONS**

*Summary: I have had 2 publications in NEJM, 18 publications in Journal of Clinical Oncology with 4 of those as First or Senior author, 23 publications in Journal of Oncology Practice with 18 of those as First or Senior author, 2 ASCO Education book publications. I also have had ASCO abstracts and written articles for OBR and other oncology business news journals.*

***Fatal Hantavirus Pulmonary Syndrome in Indiana***, NEJM Correspondence, 330:1010, 1994;  
Slama T, **Zon R**

***Hantavirus Pulmonary Syndrome in Indiana***, Indiana Medicine, 37(3): 216-218, May-June; 87(3), 1994;  
**Zon R**, Slama T

***Benign Hematologic Neoplasm Associated with Mediastinal Mature Teratoma in a Patient with Klinefelter's Syndrome: A Case Report***, Med and Ped Onc, 23: 376-379, 1994; **Zon R**, Orizu A, Neiman R, Nichols C.

***Management Strategies and Outcomes of Germ Cell Tumor Patients with Very High (>50,000 mIU/ml) HCG Levels***: **Zon R**, Nichols C, Einhorn LH; J Clin Oncol, 16(4): 1294-7, April 1998

***Correlation of Plasma VEGF (P-VEGF) with Clinical Outcome in Patients (Pts) with Metastatic Breast Cancer (MBC)***: **RT Zon**, D Neuberg, W Wood, G Sledge; ASCO Annual Meeting 1998, Abstract #712, July 1998

***Phase II Trial of Doxorubicin (DOX) and Taxotere (TXT) in Patients with Metastatic Breast Cancer***. Ansari RH, **Zon RT**, Wasielewski MJ, Critchlow RL, O'Connor C, Smith SK, Douglass L, Boughner L, Jensen L, Reasor B, Fisher L, Barnaby L. San Antonio Breast Symposium 1999, Abstract 531

***Altretamine for the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group Trial***, **RT Zon**, J McClean, D Helman, R Ansari, J Picus, A Sandler, SD Williams, PJ Loehrer. Published in Investigational New Drugs 19: 229-231, 2001

***A Retrospective Analysis to Identify Variables Predictive of Achieving a PCR After Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer***. JA Brooks, E Werner, NP Jain, PR Helft, **RT Zon**, NS Fineberg, J Leblanc, L McHenry, LH Einhorn, KA Kesler; Indiana University School of Medicine, Indianapolis, IN. ASCO Meeting Abstract #4051, July 15, 2004.



***A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC): HOG GU-0009:*** NM Hahn, W Fisher, R Langdon, **R Zon**, B Mark, CJ Sweeney. 2005 ASCO Annual Meeting, Abstract No. 4568

***Clinical Research in Private Practice: Q & A with Robin T.Zon, MD, FACP.*** KL Smith, **RT Zon**; Journal of Oncology Practice, July 1, 2005: pg. 77

***Prevention Counseling and Associated Reimbursement Come Closer to Policy Reality, Part 1.*** Journal of Oncology Practice, July 2005:50-51

***Randomized Phase III Trial of Paclitaxel with or without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer: ECOG Trial E2100.*** Abstract 7-A. Presented at the European Breast Cancer Conference, Nice, France, March 2006

***Reimbursement for Preventive Counseling Services.*** **R Zon**; Journal of Oncology Practice, Sep 2006: Vol. 2, Issue 5, 214-218

***Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis:*** NM Hahn, S Marsh, W Fisher, R Langdon, **R Zon**, M Browning, CS Johnson, TJ Scott-Horton, L Li, HL McLeod, CJ Sweeney. Clin Cancer Res 2006; 12(20): 6094-6099, October 15, 2006

***ASCO Policy Statement: The Role of the Oncology Professional in Cancer Prevention & Risk Assessment:*** **RT Zon**, E Goss, VG Vogel, RT Chlebowski, I Jatoi, ME Robson, DS Wollins, JE Garber, P Brown & BS Kramer. Journal of Clinical Oncology, February 20, 2008, Vol. 27, No. 6, 986-993

***American Society of Clinical Oncology Statement on Minimum Standards and Exemplary Attributes of Clinical Trial Sites:*** **R Zon**, NJ Meropol, RB Catalano, RL Schilsky. Journal of Clinical Oncology, May 20, 2008, Vol. 26, No. 15, 2562-2567

***A Phase II Study of Oral Enzastaurin in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane-Containing Regimen; HOG BRE05-97.*** IE Krop, KD Miller, **RT Zon**, S Isakoff, CJ Schneider, M Yu, C Johnson, LG Vaughn, OO Shonukan, GW Sledge. Abstract No. 1004, 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl)

***A Multicenter Phase II Study of Pemetrexed as Second-Line Chemotherapy for the Treatment of Hormone Refractory Prostate Cancer (HRPC); Hoosier Oncology Group GU-0367.*** NM Hahn, **RT Zon**, T Jones, F Ademuyiwa, WM Dugan, C Whalen, M Yu, R Shanmugam, T Skaar, CJ Sweeney. Abstract No. 16019, 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl)

***Guidance for Quality Research:*** **R Zon**. Journal of Oncology Practice, July 2008, Vol. 4, Issue 4, 185-187

***Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological association 2008 Clinical Practice Guideline.*** Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertson PC, Blot WJ, Carter B, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, **Zon R**, Schellhammer P. Journal of Clinical Oncology, 27:1502-1516, 2009

***Use of 5- $\alpha$ -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary,*** , Barnett S. Kramer, MD, MPH, Karen L. Hagerty, MD, Stewart Justman, PhD, Mark R. Somerfield, PhD, Peter C. Albertsen, MD, William J. Blot, PhD, H. Ballentine Carter, MD, Joseph P. Costantino, PhD, Jonathan I. Epstein, MD, Paul Godley, MD, PhD, Russell P. Harris, MD, Timothy J. Wilt, MD, MPH, Janet Wittes, PhD, **Robin Zon, MD**, and Paul Schellhammer, MD. May 2009 JOP

***A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC): Hoosier Oncology Group GU-0475.*** NM Hahn, WM Stadler, **RT Zon**, DM Waterhouse, J Picus, SR Nattam, CS Johnson, SM Perkins, MJ Waddell, CJ Sweeney. ASCO 2009 Annual Meeting, Abstract No. 5018

***Intrinsic Subtype-associated Changes in the Plasma Proteome in Breast Cancer:*** H Nakshatri, G Qi, J You, B Kerry, B Schneider, **R Zon**, C Buck, F Regnier and M Wang. Proteomics Clinical Applications 2009, 3, 1305-1313

***National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009:*** CJ Allegra, DR Aberle, P Ganschow, SM Hahn, CN Lee, S Millon-Underwood, MC Pike, SD Reed, AF Saftlas, SA Scarvalone, AM Schwartz, C Slomski, G Yothers, **R Zon**. JNCI 2010;102:161-169

***A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast Cancer (MBC):*** J O'Shaughnessy, D Miles, R Gray, V Dieras, E Perez, **R Zon**, J Cortes, X Zhou, S-C Phan, K Miller. ASCO 2010 Annual Meeting, Chicago, IL - Oral presentation; Abstract Control # 49471, permanent abstract ID # 1005.

***Commentary; Timing Is Everything:*** **R Zon**. Journal of Oncology Practice, May 2010, vol 6, Issue 3, pages 118-119

***American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases:*** AS Artz, MR Somerfield, JJ Field, AF Giusti, BS Kramer, AL Sabichi, **RT Zon**, SI Wong. Journal of Clinical Oncology, Jul 1, 2010 vol 28(19): 3199-3202

***ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases:*** **R Zon** and MN Neuss. Journal of Oncology Practice, July 2010, vol 6, Issue 4:193-194

***Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians*** Js Mandelblatt, VS Sheppard, A Hurrain, G Kimmick, C Isaacs, K Taylor, AB Kornblith, AM None, G Luta, M Tallarico, WT Barry, L Hunegs, **R Zon**, M Naughton, E Winer, C Hudis, S Edge, H Cohen and H Muss. Journal of Clinical Oncology July 1, 2010 Vol 28 (19): 3146-3153

***Mature Results from Hoosier Oncology Group GU 04-75 Phase II Trial of Cisplatin(C), Gemcitabine (G), and Bevacizumab(B) as First Line Chemotherapy for Metastatic Urothelial Carcinoma(UC).*** N Hahn, W Stadler, **R Zon**, DM Waterhouse, J Picus, SR Nattam, CS Johnson, SM Perkins, MJ Waddell C Sweeney. J Clin Oncol 28:15s, 2010 (suppl; abstr 4541)

***A Phase III Randomized, Double-blind, Placebo-controlled Study of Pilocarpine for Vaginal Dryness: NCCTG Study N04CA*** . C Loprinzi, E Balcueva, H Liu, L Kottschade, M Carlson, D Moore, **R Zon**, R Levitt, J Sloan. J Clin Oncol 28:15s, 2010 (suppl; abstr 9024)

***A Meta-analysis of Overall Survival Data From Three Randomized Trials of Bevacizumab(BV), and First-line Chemotherapy as Treatment for Patients with Metastatic Breast Cancer(MBC)***. J O'Shaughnessy, D Miles, R Gray, V Dieras, E Perez, **R Zon**, J Cortes, X Zhou, S Phan, K Miller. J Clin Oncol 28:15s, 2010(suppl;abstr 1005)

***Implementing Clinical Trials: A Review of the Attributes of Exemplary Clinical Trial Sites*** . Allison R. Baer, Gary Cohen, Dee Anna Smith, and **Robin Zon** . JOP Nov 2010:328-330.

***Part 2: Implementing Clinical Trials: A Review of the Attributes of Exemplary Clinical Trial Sites*** . **Robin Zon**, Gary Cohen, Dee Anna Smith, and Allison R. Baer. JOP Jan 2011:61-64.

***Phase II Trial of Cipslatin, Gemcitabine, and Bevacizumab AS First Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75***. Hahn NM, Stadler WM, **Zon RT**, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. J Clin Oncol. April 2011:1525-1530

***Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine (PGE) versus Erlotinib-Gemcitabine (GE) in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma***. GP Kim, NR Foster, M Salim, PJ Flynn, DF Moore, **R Zon**, RB Mowat, M Weisenfeld, AE McCullough, SR Alberts. J Clin Oncol, Vol 29,no15:4030 (May 20 Supplement), 2011:4030

***Does L-arginine/Korean ginseng/ginkgo Biloba/damiana-based Supplement Improve the Sexual Function and Quality of Life of Female Cancer Survivors: A Randomized Trial***. K Grevan, LD Case, LR Nycum, PJ Zekan, DD Hurd, EP Balcueva, GM Mills, **R Zon**, PJ Flynn, D Biggs, EG Shaw and Comprehensive Cancer Center of Wake Forest University CCOP Research Base, J Clin Oncol , Vol 29, no 15: 9016(May 20 Supplement), 2011: 9016

***The Clinical Research Team*** Allison R. Baer, **Robin Zon**, Susan Devine, and Alan P. Lyss .JOP May 1, 2011:188-192

***Achieving Exemplary Attributes With AccrualNet*** . Allison R. Baer, Jane Hajovsky, and **Robin Zon**. JOP Nov 1, 2011:e40-e4

***Treatment for The Use of Valeriana officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5)*** C.L. Barton, D.L., Atherton, P.J., Bauer, B.A., Moore, D.F., Mattar, B.I., LaVasseur, B.I., Rowland, K.M., **Zon, R.T.**, LeLindqwister, N.A., Nagargoje, G.G., Morgenthaler, T.I., Sloan, J.A., Loprinzi, Journal of Supportive Oncology, volume 9, issue 1, year 2011, pp. 24 - 31

***Assessment of Risk Evaluation and Mitigation Strategies in Oncology: Summary of the Oncology Risk Evaluation and Mitigation Strategies Workshop*** , James N. Frame, Joseph O. Jacobson, Wendy H. Vogel, Niesha Griffith, Darshan Wariabharaj, Rekha Garg, **Robin Zon**, Cynthia L. Stephens, Alison M. Bialecki, Suanna S. Bruinooge, and Steven L. Allen, JOP Mar 1, 2013:e24-e39.;

*Qualitative analysis of practicing oncologists' attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes*, Reshma Jagsi, Anne C. Chiang, Bruno C. Medeiros, Blase N. Polite, Kristen McNiff, **Robin Zon**, and Patrick J. Loehrer, *ASCO MEETING ABSTRACTS Dec 4, 2012*:56.

*Assessment of Risk Evaluation and Mitigation Strategies in Oncology: Summary of the Oncology Risk Evaluation and Mitigation Strategies Workshop*, James N. Frame, Joseph O. Jacobson, Wendy H. Vogel, Niesha Griffith, Darshan Wariabharaj, Rekha Garg, **Robin Zon**, Cynthia L. Stephens, Alison M. Bialecki, Suanna S. Bruinooge, and Steven L. Allen. *JOP Mar 1, 2013*:e24-e39; published online on October 30, 2012

*A phase II study of combined VEGF inhibitor ( bevacizumab + sorafanib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109*, Lina Mina, Menggang Yu, Cynthia Johnson, Cyndi Burkhardt, Kathy Miller, **Robin Zon**, *Invest New Drugs (2013) 31*:1307-1310

*The NCI-ASCO Cancer Trial Accrual Symposium: Summary and Recommendations*, Andrea M. Denicoff, MS, RN (Corresponding author) National Cancer Institute, Wortia McCaskill Stevens, MD, MS, Stephen S. Grubbs, MD, Suanna S. Bruinooge, BA, Robert L. Comis, MD, Peggy Devine, David M. Dilts, PhD, MBA, MA, Michelle E. Duff, DPT, Jean G. Ford, MD, Steven Joffe, MD, MPH, Lidia Schapira, MD, Kevin P. Weinfurt, PhD, Margo Michaels, MPH, Derek Raghavan, MD, PhD, Ellen S. Richmond, MS, RN, **Robin Zon**, MD, FACP, FASCO, Terrance L. Albrecht, PhD, Michael A. Bookman, MD, Afshin Dowlati, MD, Rebecca Enos, RN, MPH, Mona N. Fouad, MD, MPH, Marjorie Good, RN, BSN, MPH, OCN, William J. Hicks, MD, Patrick J. Loehrer, Sr., MD, Alan P. Lyss, MD, Steven N. Wolff, MD, Debra M. Wujcik, PhD, RN, FAAN, Neal J. Meropol, MD, *JOP Nov 1, 2013*:267-276; published online on October 15, 2013

*The Changing Face of Research in Community Practice*, **Robin Zon** MD, FASCO, FACP, Suanna Bruinooge, and Alan Lyss, MD., *JOP*, vol 10(3): 155-160, May 2014

*Reforming the Community Research Program: From Community Clinical Oncology Program to the National Cancer Institute Community Oncology Research Program*, **Robin Zon**, MD, FACP, FASCO, *Education Book for ASCO Annual Meeting 2014*

*The Clinical Trial Assessment of Infrastructure Matrix Tool (CT AIM) to Improve the Quality of Research Conduct in the Community*. Dimond EP, **Zon R**, St. Germain DC, et al ASCO Annual Meeting 2014, abstract no. 126390

*Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106*

Kathryn M Greven<sup>1</sup>, L Douglas Case, Lawrence R Nycum, Patricia J Zekan, David D Hurd, Ernie P Balcueva, Glenn M Mills, **Robin Zon**, Patrick J Flynn, David Biggs, Edward G Shaw, Glenn Lesser, Michelle J Naughton, *J Community Support Oncol.* 2015 Mar;13(3):87-94.

*ReCAP: Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community / Original Contribution: Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community*

Eileen P. Dimond, **Robin T. Zon**, Bryan J. Weiner, Diane St. Germain, Andrea M. Denicoff, Kandie Dempsey, Angela C. Carrigan, Randall W. Teal, Marjorie J. Good, Wortia McCaskill-Stevens, Stephen S. Grubbs, *JOP Jan 1, 2016*:63-64; published online on December 1, 2015

**ASCO Special Articles :American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology : Robin T. Zon**, James N. Frame, Michael N. Neuss, Ray D. Page, Dana S. Wollins, Steven Stranne, and Linda D. Bosserman. JOP Mar 1, 2016;261-266; published online on January 12, 2016

**The ASCO Perspective on Oncology Clinical Pathways : Interview Dr. Robin Zon** , March 2016, Journal of Clinical Pathways

**ASCO Special Article :American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology :Zon RT**, Edge SB, Page RD, et al. Journal of Oncology Practice. 2017;13(3):207-210.

**Clinical Pathways n Community Oncology : Assessing the Work of the American Society of Clinical Oncology Task Force on Clinical Pathways- Interview Dr. Robin Zon** , January/February 2017, Journal of Clinical Pathways

**The Path Forward : Pathways and Practice Transformation, Robin Zon MD** , ASCOconnection.org, 11/2017

**Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies HOG LUN 07-130** ,Jalal, Shadia I. MD<sup>\*†</sup>; Hanna, Nasser MD<sup>\*†</sup>; Zon, Robin MD<sup>‡</sup>; Masters, Gregory A. MD<sup>§</sup>; Borghaei, Hossein DO<sup>||</sup>; Koneru, Karuna MD<sup>¶</sup>; Badve, Sunil MD<sup>†#</sup>; Prasad, Nagendra PhD<sup>\*†</sup>; Somaiah, Neeta MD<sup>\*\*</sup>; Wu, Jingwei MS<sup>††</sup>; Yu, Zhangsheng PhD<sup>††</sup>; Einhorn, Lawrence MD<sup>\*†</sup>  
American Journal of Clinical Oncology: August 2017 - Volume 40 - Issue 4 - p 329-335

**Summary of the Workshop on the Safe Handling of Hazardous Drugs Cohosted by the National Institute for Occupational Safety and Health and the American Society of Clinical Oncology**  
Thomas H. Connor, Paul Celano, James N. Frame, and **Robin T. Zon**, Journal Of Oncology Practice, 2017;13(3)

**Editorials : USP<sup>3</sup>: United in Safeguarding Patients, Personnel, and Providers**  
**Robin T. Zon** Journal of Oncology Practice 2017;13(3)

**The Path Forward for Clinical Pathways in Oncology, Robin T Zon**, ASCO Post Editorial, Volume 8, Issue 5, March 25, 2017

**Perspectives on the Use of Clinical Pathways in Oncology Care** Anne C. Chiang, MD, PhD, Peter Ellis, MD, and **Robin Zon, MD** , 2017 ASCO Annual Meeting Education Book, page 155

**Association of 70-Gene Signature Assay Findings with Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay** , Michaels Tsai MD;Shelly Lo MD; William Audeh MD; Rubina Qamar MD; Raye Budwat MD; Elis Levine MD; Pat Whitworth MD; Blanche Mavromatis MD; Robin Zon MD; Dwight Oldham MD; Sarah Untch MS; Tina Treece PhD; Lisa Blumencranz PhD; Hatem Soliman Md. JAMA Oncology, January 2018 vol 4 (1)

**ASCO Daily News Annual meeting, Expert Opinion, June 5, 2017: The Path Forward: Pathways and Practice Transformation, Robin Zon**

***Oncology Clinical Pathways: Charting the Landscape of Pathway Providers***

Bobby Daly, **Robin T. Zon**, Ray D. Page, Stephen B. Edge, Gary H. Lyman, Sybil R. Green, Dana S. Wollins, Linda D. Bosserman MAR 2018 Journal of Oncology Practice

***When Investment Meets Return*** :Robin Zon, Ray Page MAR 2018 Jrnl Onc Practice

***American Society of Clinical Oncology Statement: Biosimilars in Oncology***

Gary H. Lyman, Edward Balaban, Michael Diaz, Andrea Ferris, Anne Tsao, Emile Voest, **Robin Zon**, Michael Francisco, Sybil Green, Shimere Sherwood, R. Donald Harvey, Richard L. Schilsky  
APR 2018 Journal of Clinical Oncology

***Rationale, Opportunities, and Reality of Biosimilar Medications.***

Gary H Lyman MD MPH, Robin Zon MD, R.Donald Harvey Phram D and Richard Schilsky,MD  
New England Journal of Medicine, May 24, 2018- 38(21): 2036

**Reply to S.D. Lucio** Gary H Lyman MD MPH, Robin Zon MD, R.Donald Harvey Phram D and Richard Schilsky,MD JCO volume 36( 20) July 10, 2018

***Safe Handling of Hazardous Drugs: ASCO Standards*** Paul Celano, Chrisopher Fausel, Erin Kennedy, Tim Miller, Thomas Oliver, Ray Page, Jeffrey Ward, and **Robin Zon** Journal of Clinical Oncology 37: 598-609, 2019

***Safe Handling of Hazardous Drugs: ASCO Standards Summary*** Paul Celano, Erin Kennedy and **Robin T Zon** Journal of Oncology Practice Volume 15, (2) : 112- 115 ,2019

***ASCO Standards for Safe Handling of Hazardous Drugs*** Paul Celano, Erin Kennedy, Thomas Oliver and **Robin T Zon** Journal of Oncology Practice Volume 15(2): 65-66, 2019

***ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy***, Nasser Hanna Senior author Journal of Thoracic Oncology, vol 14(10), October 2019

***Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology*** Reshma Jagsi MD DPhil, Kent Griffith MS, Richelle Jones MS, Chris Krenz BA, Michel Gornick PhD, Rebecca Spence JD, Raymond De Vries PhD, Sarah T. Hawley PhD,MPH, Robin Zon MD FACP , Sage Bolte PhD, Navid Sadeghi MD, Richard Shilsky MD FACP FASCO , Angela Bradbury MD , JCO no 34 ( Dec 1 ,2019) 3203-3211

***A Phase II Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Cancer Research Network (HCRN) LUN 14-17*** Greg Durm MD, Salma Iabbour MD, Sandra Althouse MS, Ziyue Liu OhD, Ahad Sadiq MD, **Robin T Zon MD**, Shadia Jalal MD, .Nasser Hanna MD. Cancer, July 22,2020 Published as Early View , <https://doi.org/10.1002/cncr.33083>

***The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.***Nikhil Shukla, Sandra K. Althouse, Ahad Ali Sadiq, Shadia Ibrahim Jalal, Salma K. Jabbour, **Robin Zon**, Goetz H. Kloecker, William B. Fisher, Karen L. Reckamp, Ebenezer A. Kio, Robert M. Langdon, Bamidele Adesunloye, Ryan D. Gentzler, Nasser H. Hanna, Greg Andrew Durm. Journal of

***N083E( Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER-2 positive breast cancer.*** Breast Cancer Research and Treatment , August 2020 Roberto A Leon-Ferre<sup>1</sup>, Edith A Perez<sup>2</sup>, David W Hillman<sup>3</sup>, Celyne Bueno<sup>4</sup>, Alejandra T Perez<sup>5</sup>, Beiyun Chen<sup>6</sup>, Robert B Jenkins<sup>6</sup>, Donald W Northfelt<sup>7</sup>, David B Johnson<sup>8</sup>, Robert L Carolla<sup>9</sup>, **Robin T Zon<sup>10</sup>**, Alvaro Moreno-Aspitia<sup>11</sup>  
DOI: [10.1007/s10549-020-05709-z](https://doi.org/10.1007/s10549-020-05709-z)

***Patient Preferences Regarding Informed Consent Models for Participation in a Learning Healthcare System for Oncology*** ,Rochelle D. Jones, Chris Krenz, Michele Gornick, Kent A. Griffith, Rebecca Spence, Angela R. Bradbury, Raymond De Vries, Sarah T. Hawley, Rodney A. Hayward, **Robin Zon**, Sage Bolte, Navid Sadeghi, Richard L. Schilsky, Reshma Jagsi  
SEP 2020, JCO ONCOLOGY PRACTICE

***American Society of Clinical Oncology Road to Recovery Report: Learning From the Covid-19 Experience to Improve Clinical Research and Cancer Care – Robin Zon*** listed as one of the coauthors. First author Nathan Pennell, MD PHD, second author Melissa Dillmon, Md and Senior author Howard Burris III MD. ASCO Special Article 2020

***Telehealth in Oncology: ASCO Standards and Practice Recommendations: Robin T. Zon***, Erin B. Kennedy, Kerin Adelson, Sibel Blau, Natalie Dickson, David Gill, Nicole Laferriere, Ana Maria Lopez, Therese M. Mulvey, Debra Patt, Todd A. Pickard, Terry Purdom, Trevor J. Royce, Ashley L. Sumrall, and Ray D. Page JCO Oncology Practice 2021 17:9, 546-564

***Recommendations for Enhancing the Value of Clinical Pathways: Findings From the 2020 Care Pathways Working Group*** Winston Wong PharmD, Gordon Kuntz, **Robin T Zon** MD FACP FASCO, Vasily Belozerooff PhD, 2020 Care Pathways Working Group. Jrnl of Clinical Pathways, Nov 2021:36-47

## **JOURNAL WORK**

JOP reviewer from 2011-2022  
Editorial Advisory Board for Journal of Clinical Pathways  
\_Acknowledgement of Reviewers and authors JOP 2017  
Acknowledgment of Reviewers JOP Feb 1, 2016:e268-e269  
Acknowledgment of Authors JOP Jan 1, 2015:e110-e112  
Acknowledgment of Reviewers JOP Jan 1, 2015:e113  
Acknowledgment of Reviewers JOP Jan 1, 2014:e13  
Acknowledgment of Authors JOP Jan 1, 2013 :e20  
Acknowledgment of Reviewers JOP Jan 1, 2013:e20  
Acknowledgment of Authors JOP Jan 1, 2012:e14-e15  
Acknowledgment of Reviewers JOP Jan 1, 2012:e16  
Acknowledgment of Authors JOP Nov 1, 2006:319

## **Presentations:**

Numerous Presentations to community groups, interviews on television, radio and newsprint as well as interviews with a number of paper journals such as Oncology Times, AACR, Journal of Clinical Pathways,

OBR,etc. Estimated over 150 interviews and presentations not noted in above CV over 25 year timeframe.  
Recorded 5 podcasts as of July 2022

### **PROFESSIONAL MEMBERSHIPS**

America Medical Association

American Society of Clinical Oncology ( 1997-present)

American College of Physicians, Fellow (ACP)

Hoosier Oncology Group (HOG) aka Hoosier Cancer research Network

Indiana Medical Oncology Society (IMOS)- ASCO State Affiliate

Alpha Omega Alpha

St. Joseph County Medical Society, Indiana State Medical Association (ISMA)

South Bend Medical Foundation 1999- present .Current Chair of the Board and CEO Search committee

### **HONORS AND AWARDS( College-Medical School)**

Insignis Scholar – full tuition scholarship 1978-1982

Alpha Sigma Nu (Jesuit Honor Society)

American Chemical Society Scholarship

Dean's Academic List 1978-1982

Rod Fasone Research Scholarship (Oncology)

Alpha Omega Alpha 1991

Dr. E.B. Rinker Scholarship for academic achievement

1991 First Pitch at South Bend Cubs 2017